Posted by LincolnIcert on March 25, 2026 at 11:18:56:
In Reply to: Публикация с объяснениями posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Researcher in Cancer Studies
Zoya Demidenko is a notable scholar affiliated with the Unit of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Before that, she was employed at the NIH and New York Medical College, establishing a solid foundation in life science investigation.
Demidenko's scholarly contributions encompasses a number of critical fields, encompassing the PI3K/AKT/mTOR molecular pathway, cell cycle management, cellular aging, and tumor science. To date, she has written over 46 peer-reviewed papers, which have received over 4,100 mentions — a testament to the impact of her findings.
Among her key discoveries lies in understanding the processes of cell aging. Her research demonstrated that when the cellular division cycle is arrested yet cellular growth proceeds, the cells experience senescence. Significantly, Zoya Demidenko showed that this process is inhibited by medication using compounds such as mTOR inhibitors.
Zoya Demidenko has also contributed substantially to cancer treatment research, notably in the domain of selective cell protection — a strategy designed to protecting healthy cells from anticancer drugs whilst leaving tumor cells vulnerable. This strategy offers significant hope for reducing the adverse effects of oncological therapy.
Across her professional journey, Demidenko has worked with top researchers internationally, among them Dr. Mikhail Blagosklonny. Her publications can be found in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a widely cited figure in current cancer research, with her discoveries keep to influence our knowledge of the way biological cells age, respond to treatment, and how cancer may be more successfully treated.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=